You are here: Home Media News
ECH newsletter
Sign up for the ECH newsletter and stay informed about homeopathy in Europe
(Required)
 

News

Here you can find news about developments in Europe that are important for homeopathy, news from the European homeopathic community and from the ECH itself

The whole news archive is available below

Proving shows significant distinction between Aconitum C30 and placebo

Just recently a new study conducted in Switzerland has significantly demonstrated a distinction between the proving symptoms of Aconitum napellus C30 and a placebo. This is another study published in an academic journal that has found substantial effects from high potencies in randomly selected, healthy test subjects when compared with placebo.

Participants and Methods:
From the 33 subjects randomized for this double-blind, placebo-controlled crossover study, 27 could be included in the analysis. The study comprised two 7-day-long treatment periods, each including the intake of a study preparation for 3 days and a wash-out period of 4 days. One group was first treated with Aconitum napellus C30 and then with placebo; the other group received the two study preparations in the reverse order. The signs and symptoms before the first treatment and after each treatment were collected, evaluated, weighted and repertorized. Based on this classification the blinded physician assessed these signs and symptoms as study outcome parameter to represent the responses to each of the study preparations. Statistical analysis of the data was performed using the Wilcoxon-Mann-Whitney rank test.

Results:
Crossover differences yielded statistical significance between the classified reactions towards Aconitum napellus C30 and to placebo (p = 0.004). Conclusions: A clear difference between the reported short-term reactions of healthy subjects towards Aconitum napellus C30 and towards placebo was shown. The crossover design with intra-individual comparisons proved to be adequate to recognize the study preparations and for the statistical analysis of a small population sample.

Reference:
Piltan D, Rist L, Simões-Wüst P, Saller R (2009). Test of a homeopathic dilution of Aconitum napellus. A clinical, randomized, double-blind, controlled crossover study in healthy volunteers. Forschende Komplementärmedizin, 16:168-73.

[Abstract on PubMed]
[Paper can be downloaded from the publisher's website]

Share |

Nobel Prize winner reports effects of homeopathic dilutions

In a recent study Professor Luc Montagnier, a French virologist who co-discovered HIV and who won the Nobel Prize in 2008, and his team report the results of a series of rigorous experiments investigating the electromagnetic properties of highly-diluted biological samples.

The study demonstrates that some bacterial DNA sequences are able to induce electromagnetic waves at high aqueous dilutions. It appears to be a resonance phenomenon triggered by the ambient electromagnetic background of very low frequency waves. The researchers used aqueous solutions that were agitated and serially diluted (the researchers note that the solutions were 'strongly agitated' and that this step was 'critical for the generation of signals'). In other words homeopathic potencies, although the word 'homeopathy' is not mentioned in the article.

The researchers found that pathogenic bacteria and viruses show a distinct electromagnetic signature at dilutions ranging from 10^-5 to 10^-12 (corresponding to 5D to 12D) and that small DNA fragments (responsible for pathogenicity) were solely accountable for the electromagnetic signal. The researchers also noted that one experiment found significant effects from dilutions as high as 10^-18 (equivalent to 18D).  The electromagnetic signature changed with dilution levels but was unaffected by the initial concentration and remained even after the remaining DNA fragments were destroyed by chemical agents.

They observed that the electromagnetic signal was destroyed by heating or freezing the sample. Also, a 'cross-talk' effect was found whereby a negative sample inhibits the positive signal in another sample if they are left together overnight in a shielded container. The researchers propose that specific aqueous nanostructures form in the samples during the dilution process and are responsible for the electromagnetic effects measured.

The researchers also detected the same electromagnetic signals in the plasma and in the DNA extracted from the plasma of patients suffering from Alzheimer disease, Parkinson disease, multiple sclerosis, and rheumatoid arthritis.

This study is an important contribution to the growing evidence base in fundamental research with direct relevance to homeopathy.

Reference
Montagnier L, Aissa J, Ferris S, Montagnier J-L, Lavallee C (2009). Electromagnetic Signals Are Produced by Aqueous Nanostructures Derived from Bacterial DNA Sequences. Interdisciplinary Sciences: Computational Life Sciences, 1: 81-90.
[the paper can be downloaded here]

Share |

Individualised homeopathy as effective as Prozac

A research group at the Federal University of Sao Paulo, Brazil recently demonstrated that the effectiveness of individualized homeopathy was statistically equivalent to fluoxetine (Prozac), a standard effective treatment in acute depression.

Ninety-one outpatients with moderate to severe depression were assigned to receive an individualized homeopathic medicine or fluoxetine 20 mg per day (up to 40 mg per day) in a prospective, randomized, double-blind double-dummy 8-week, single-center trial.

Primary efficacy measure was the analysis of the mean change in the Montgomery & Åsberg Depression Rating Scale (MADRS) depression scores, using a non-inferiority test with margin of 1.45. Secondary efficacy outcomes were response and remission rates. Mean MADRS scores differences were not significant at the 4th (P1/40.654) and 8th weeks (P1/40.965) of treatment.

Non-inferiority of homeopathy was indicated because the upper limit of the confidence interval (CI) for mean difference in MADRS change was less than the non-inferiority margin: mean differences (homeopathy–fluoxetine) were 3.04 (95% CI 6.95, 0.86) and 2.4 (95% CI 6.05, 0.77) at 4th and 8th week, respectively. There were no significant differences between the percentages of response or remission rates in the homeopathy group vs. the fluoxetine group.

Patients treated with fluoxetine reported more troublesome side effects and there was a trend toward greater treatment interruption for adverse effects in the fluoxetine group. This study illustrates the feasibility of randomized controlled double-blind trials of homeopathy in depression and indicates the non-inferiority of individualized homeopathic medicines as compared to fluoxetine in acute treatment of outpatients with moderate to severe depression.

The study can be downloaded here.

Share |

EU awards € 1.5 million grant for CAM research

Within the 7th Research Framework Programme of the European Union a pan-European consortium of researchers has been selected to carry out a project on Complementary and Alternative Medicine (CAM): CAMbrella. The consortium includes researchers from the departments for Complementary Medicine at various universities and institutes in Austria, Denmark, France, Germany, Hungary, Italy, Norway, Romania, Spain, Sweden, Switzerland, and the United Kingdom.

The expected EU contribution will be € 1.498.598. The aim of this project is to develop a roadmap for future European research in CAM that is appropriate for the health care needs of EU citizens, and acceptable to the EU Parliament, as well as their national research funders and healthcare providers. The specific objectives are to develop an EU network involving centres of research excellence for collaborative research, to develop consensus-based terminology widely accepted in Europe to describe the major CAM interventions used clinically in Europe, to create a knowledge base that allows to accurately evaluate the patient demands for CAM and its prevalence, to review the current legal status and policies governing CAM provision in the EU and, to explore the needs, beliefs and attitudes of the EU citizens with respect to CAM. Based on this information, a roadmap will be created that will enable a sustainable and prioritised EU research roadmap for CAM.

These overall objectives will be achieved in 3 years. The project will be managed by a Steering Committee with the support of a Scientific Committee and an Advisory Board and will involve all the major European stakeholders in the field of CAM.

Share |

Homeopathy works in eczema and psoriasis

In 2006 a prospective, multi-centre cohort study was conducted by a research team at Berlin’s Charité University (Germany), including 103 primary care practices with additional specialization in homeopathy in Germany and Switzerland. In this study the use and effects of homeopathy under conditions of usual care were investigated. The study involved 3981 patients who consulted a physician for classical homeopathic therapy in 103 primary care practices in Germany and Switzerland. Disease severity and quality of life demonstrated marked and sustained improvements following homeopathic treatment period. The study indicates that homeopathic medical therapy may play a beneficial role in the long-term care of patients with chronic diseases.

In recent publications the results of homeopathic treatment in two subgroups of the above-mentioned study were described, one subgroup of children with atopic eczema and another subgroup of 82 adults with psoriasis.

The study on atopic eczema included 225 children with a disease duration of 3.6 ± 3.8 years who were followed up for 24 months. Over the course of the study patients received 7.3 ± 6.4 homeopathic prescriptions, most frequently Calcium carbonicum (8.2%), Tuberculinum (7.2%), and Medorrhinum (6.8%). In total, 137 different homeopathic remedies were used. The strongest improvement in diagnoses and medical complaints was seen in the first 3 months, and it continued during the full observation period. After 24 months, the atopic eczema as well as the other baseline diagnoses were considerably relieved, while reductions in use of conventional medicines were observed.

The other study was aimed at evaluating details and effects of homeopathic treatment in patients with psoriasis. Forty-five physicians treated 82 adults, who had had psoriasis for an average of 14.7 years and of whom 96.3% had been treated before. Patients received 6.0 ± 4.9 homeopathic prescriptions. Diagnoses and complaints severity improved markedly with large effect sizes. In addition, the quality of life improved, while conventional treatment and health service use were considerably reduced.

It has to be kept in mind that these are not experimental studies (with control group, randomization, and blinding, but observational studies which are, by their character, less rigorous than experimental studies. The aim of these studies was to provide systematic and detailed information about status and effects of homeopathic medical care in usual care. And the results clearly demonstrate that under individualized (‘classical’) homeopathic treatment, patients with atopic eczema and psoriasis improved in symptoms and quality of life.

References:

Witt CM, Lüdtke R, Baur R, Willich SN. (2005) Homeopathic Medical Practice: Long-term results of a Cohort Study with 3,981 Patients. BMC Public Health, 5:115.

Witt CM, Lüdtke R, Willich SN (2009). Homeopathic treatment of children with atopic eczema: a prospective observational study with two years follow-up. Acta Dermato-venereologica, 89:182-183.

Witt CM, Lüdtke R, Willich SN (2009) Homeopathic treatment of patients with psoriasis--a prospective observational study with 2 years follow-up. Journal of the European Academy of Dermatology and Venereology, 23:538-543.

Share |
Document Actions
Share |